Milestone Pharmaceuticals Inc.
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $238.0K
- Net income
- -$63.1M
- Total assets
- $113.6M
- Market cap
- $153.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$62.1M
- Net income
- -$63.1M
- EPS (basic)
- $-0.75
- EPS (diluted)
- $-0.75
Balance sheet
- Total assets
- $113.6M
- Current assets
- $111.9M
- Total liabilities
- $71.8M
- Current liabilities
- $14.0M
- Shareholders’ equity
- $41.8M
Cash flow
- Operating cash flow
- -$49.0M
- Investing cash flow
- $11.2M
- Financing cash flow
- $85.5M
- Net cash flow
- $47.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $153.1M
- EPS (diluted)
- $-0.75
- Shares outstanding
- 124.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $63.1M in FY2026.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Milestone Pharmaceuticals Inc..
Write a review
News about Milestone Pharmaceuticals Inc.
News & sentiment via Polygon.io
